登录 | 注册    关注公众号  
微信公众号
搜索
 > 【CLEC12A】

CLEC12A信息

英文名称:C-Type lectin domain family 12 member A
中文名称:C型凝集素结构域家族12成员A
靶点别称:CD371 Antigen,C-Type Lectin-Like Molecule 1,MICL,CD371,CLEC12A,DCAL2,DCAL-2,Dendritic cell-associated lectin 2,C-Type Lectin Domain Family 12 Member A,Myeloid Inhibitory C-Type Lectin-Like Receptor,CLL-1,CLL1,C-Type Lectin Domain Family 12, Member A,C-Type Lectin-Like Molecule-1,C-Type Lectin Protein CLL-1
上市药物数量:0
临床药物数量:8
最高研发阶段:临床一期

CLEC12A产品列表

 
评论(2)
CLA-H5245|Human CLEC12A / MICL / CLL-1 Protein, His Tag
  1. 136XXXXXXX0
  2. 0人赞
  3. 购买该蛋白用于小鼠免疫,该蛋白纯度高,免疫原性强,多次购买,经过实验验证,使用该蛋白对小鼠进行免疫,可以达到较高的滴度,所以多次购买该产品。
  4. >
  5. 2022-09-15
CLA-HA248|APC-Labeled Human CLEC12A / MICL / CLL-1 Protein, His Tag (Site-specific conjugation)
  1. 178XXXXXXX2
  2. 0人赞
  3. 该产品用于白血病干细胞的有希望的标志物,实验过程中使用起来很是灵敏,简便,易于检测。使用中非常稳定,未出现异常,以后还会购买。
  4. 2022-11-16
 

CLEC12A 分子别名

CLEC12A,MICL,CLL-1,CLL1,DCAL2,DCAL-2,CD371

CLEC12A 分子背景

CLEC12A (C-type lectin domain family 12 member A) is also known as CLL1, DCAL2, MICL. Clec12a is an inhibitory receptor for uric acid crystals that regulates inflammation in response to cell death. Cell surface receptor that modulates signaling cascades and mediates tyrosine phosphorylation of target MAP kinases. Evidence of distinct disease propagating stem cells in myelodysplastic syndrome (MDS) has emerged in recent years. The role of CLEC12A in MDS, however, remains to be elucidated. Furthermore, CLEC12A has been proposed as a promising marker of leukaemic stem cells in AML.

CLEC12A 前沿进展

CLEC12A临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Anti-CD33/CLL-1 CAR-T (Legend) 临床一期 急性早幼粒细胞白血病 详情
CLL-1.CAR T cell therapy (Baylor College of Medicine) 临床一期 贝勒医学院 急性髓细胞样白血病 详情
ICG-136 ICG-136; 123b-33bcCAR 临床一期 急性髓细胞样白血病 详情
Tepoditamab MCLA-117 Pharmaceutical Research Associates, Institute Gustave-Roussy, Merus, Vu University Medical Center, Lgc 详情
Anti-CLL1 CAR T cell therapy 详情
Anti-CD33/CLL1 CAR-NK Cell Therapy 临床一期 安渡生物医药(杭州)有限公司 急性髓细胞样白血病 详情
CLL1 CAR T-cell Therapy(Yake Biotechnology) 上海雅科生物科技有限公司 详情
CD123/CLL1 CAR-T Cell Therapy (Fujian Medical University) 福建医科大学 详情
CLL1-CD33 cCART cell therapy (iCell Gene Therapeutics) CLL1-CD33-cCAR 临床一期 归气丹生物医药(香港)有限公司, 成都军区总医院 慢性髓细胞白血病, 血液肿瘤, 骨髓增生性疾病, 骨髓增生异常综合征, 急性髓细胞样白血病 详情
KITE-222 临床一期 Kite Pharma 急性髓细胞样白血病 详情
CLL1 CAR-T(Zhejiang University) 临床一期 浙江大学 急性髓细胞样白血病 详情
CLL1+CD33 CAR-T(Zhejiang University) 临床一期 浙江大学 急性髓细胞样白血病 详情

消息提示

请输入您的联系方式,再点击提交!

确定